Genzyme Corporate Research Search Genzyme Websites
Patients and FamiliesHealth Care ProfessionalsAbout Genzyme Therapeutics
Fabry Community HomeFabry Community
Health Care Professional Overview
About Fabry Disease
Signs and Symptoms
Genetics of Fabry Disease
Diagnosing Fabry
Disease Monograph
Current Treatments
The Fabry Registry
Genzyme Support
Resources

Genetics and inheritance of Fabry disease

The alpha-GAL gene

The alpha-GAL gene is localized to the long arm of the X chromosome (locus Xq22.1). [1] The gene, which encodes a 429 amino acid polypeptide; including a 31 amino acid signal peptide, is 12 kilobases long and contains 7 exons. [2] The defect that causes Fabry disease is heterogeneous - to date, over 200 mutations of the alpha-GAL gene have been recorded in the Human Mutation Database. Moreover, most families have “private” mutations (found only in that family) [3] that may explain variations in the clinical presentation of Fabry disease.

Inheritance

Fabry is an X-linked recessive disease. It is inherited through the mother who, with each conception, has a 50% chance of passing the defective gene on to all offspring. Her sons who inherit the gene will have Fabry disease. Daughters who inherit the gene will be carriers. Because of X-chromosomal inactivation, some female carriers develop symptoms of mild, moderate, or classical Fabry disease. [1]

Males with Fabry disease pass on the defective gene to none of their sons and all of their daughters.

Although a positive family history is a strong indicator for Fabry disease, de novo or spontaneous mutations have been documented. [4, 5] Thus, absence of a family history does not rule out a diagnosis of Fabry disease.

References

1. Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw Hill, 2001;3733-3774.

2. Bishop DF, Kornreich R, Desnick RJ. Structural organization of the human alpha-galactosidase gene: Further evidence for the absence of a 3’ untranslated region. Proc Natl Acad Sci U S A. 1988;85:3903-3907.

3. Ashton-Prolla P, Ashley GA, Giugliani R, Pires RF, Desnick RJ, Eng CM. Fabry disease: comparison of enzymatic, linkage, and mutation analysis for carrier detection in a family with a novel mutation (30delG). Am J Med Genet. 1999;84:420-424.

4. Hasholt L, Sorensen SA, Wandall A, Andersen EB, Arlien-Soborg P. A Fabry's disease heterozygote with a new mutation: biochemical, ultrastructural, and clinical investigations. J Med Genet. 1990;27:303-306.

5. Redonnet-Vernhet I, Ploos van Amstel JK, Jansen RP, Wevers RA, Salvayre R, Levade T. Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. J Med Genet. 1996;33:682-688.

Keyword: 
Search In: 
New Page 1
Fabry Voices
""

More Fabry patient profiles
Resources
Medical Information Services
Request Materials
Publications
Events Calendar
Related Links
Fabry Registry

First Symptoms to Diagnosis

Data from the Fabry Registry confirms the large gap between the average age of symptoms onset (10.5) and diagnosis of Fabry disease (28.5). To learn more about the importance of the Fabry Registry click here.

Contact Information
Genzyme Therapeutics
500 Kendall Street
Cambridge, MA 02142
617 768 9000
800 745 4447

Genzyme Europe BV
Gooimeer 10
1411 DD Naarden
The Netherlands
31 35 699 1200
Contact Genzyme


Terms and Conditions of Use | Privacy Policy | © 2003-2008 Genzyme Corporation. All rights reserved.| © Fabr/US/P219/08/05
Genzyme Therapeutics